LASA · Lasa Supergenerics Ltd · Biotechnology & Drugs
LASA · Lasa Supergenerics Ltd · Biotechnology & Drugs
As of 02 Nov close
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹1 Cr
Revenue YoY
PAT YoY
+83.0%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
1
P/S (TTM)
5
Sector P/E
Not available from data source
Dividend yield
0.0%
Source: Yahoo Finance, as of 29 Oct 2026
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| LASA (this stock) | Not meaningful (earnings negative over the last 12 months) | 1 | -260.4% | -68.7% | 0.2 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
rising 1q
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedLasa Supergenerics Limited (LASA) reported a significant net loss of Rs. 3,409.03 Lakhs for FY2025-26, driven by a sharp decline in revenue to Rs. 2,514.07 Lakhs from Rs. 14,244.81 Lakhs in the prior year. The company faces material uncertainty about its ability to continue as a going concern due to operational suspension following a fire incident on 18 May 2025, which caused extensive damage to assets and disrupted operations. The company has not resumed operations and is dependent on obtaining statutory clearances, resolving liabilities, and securing financial resources. The auditor issued a qualified opinion due to insufficient evidence on asset impairment, contingent liabilities from GST and income tax disputes, and unresolved issues related to the fire incident. The company has also written off bad debts and is managing liquidity through asset disposals.
- Net loss of Rs. 3,409.03 Lakhs for FY2025-26 with revenue declining to Rs. 2,514.07 Lakhs.
- Material uncertainty about going concern due to operational suspension post-fire incident on 18 May 2025.
- Qualified auditor's opinion due to insufficient evidence on asset impairment, contingent liabilities, and unresolved fire incident impact.
- Contingent liabilities include GST demands of Rs. 3,810.93 Lakhs and income tax disputes of Rs. 86.42 Crs.
- Company has written off bad debts and is managing liquidity through asset disposals.
Key takeaway: Lasa Supergenerics Limited faces significant financial and operational challenges, including a substantial net loss, operational suspension due to a fire incident, and unresolved legal and tax disputes, raising material uncertainty about its ability to continue as a going concern.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (1 item); Regulatory Action (2 items); Default / Covenant Breach (2 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
1 occurrenceEarlier (1-3 years ago)
The auditor has drawn attention to Note 27 of the Financial Results, highlighting advances of Rs.470 Lacs paid to Arch Herbals Pvt Ltd in the Financial Year 2020 and 2021.
Regulatory Action
2 occurrencesEarlier (1-3 years ago)
The company missed compliance with Regulation 3(5) and 3(6) of SEBI's Insider Trading Regulations for the quarter and year ended 31.03.2024, and was fined Rs.118800/- by BSE and NSE.
The company was fined Rs.59,400 by BSE and Rs.59,400 by NSE for non-compliance in submitting financial results and related party transactions after the due date. Additionally, it was fined Rs.29,500 by each exchange for non-compliance with SEBI's board composition regulations.
Default / Covenant Breach
2 occurrencesEarlier (1-3 years ago)
The company has defaulted on repayment of a long-term bank borrowing from Bank of Baroda (Dubai) with an outstanding principal amount of 22,18,60,771/-, which remains unpaid for 2110 days.
Bank of Baroda has filed a petition under Section 7 of the Insolvency and Bankruptcy Code, 2016, alleging a default in payment of ₹26,79,46,546.25, seeking initiation of Corporate Insolvency Resolution Process (CIRP) against Lasa Supergenerics Limited, which is still pending at the admissions stage.
Routine disclosures
Related-Party Transaction
1 occurrenceEarlier (1-3 years ago)
The company did not comply with Regulation 23(9) of SEBI (LODR) Regulation, 2015, by submitting the disclosure of related party transactions one day after the due date for the quarter and the year ended 31.03.2024.
Management & Board Governance
2 occurrencesEarlier (1-3 years ago)
Mr. Umesh S. Pawar, Whole Time Director resigned w.e.f 13th May, 2025. Mrs. Mitti Jain, Company Secretary and Compliance Officer resigned w.e.f 29th August 2025.
Mr. Ravi Shankar Kabra, Chief Financial Officer resigned from the post w.e.f 25th April, 2024.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
2.29% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).